VC  Lumira Capital

     Office Locations:

303 Wyman Street, Suite 300
Waltham, MA 02451
Phone: 781-530-3868
Fax: 253-484-4262

Get all office locations for this firm with a National Database subscription.


  • Expansion



  • Life Sciences & Healthcare
  • Medical Device



    Lumira Capital primarily invests in later stage biopharmaceutical companies typically having at least preliminary clinical proof of concept data and will also consider later stage medical device companies. The firm's history goes back to 1989 when the company was established as MDS Capital Corp. The company changed its name to Lumira Capital in September 2007 as part of a corporate repositioning to build on its strength in the North American health and life science sector. Typically, Lumira's initial investment size is $5 to 10 million, and the firm concentrates its investments in the U.S. and Canada.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Andy Haigh PhD, MBA Senior Associate
    Beni Rovinski PhD Managing Director
    Brian Underdown PhD Managing Director
    Daniel Hetu MD, MBA
    Gerry Brunk MBA Managing Director


    Recent Funding Events (trailing 12 months):










      Series D


      Cardiac Dimensions



      Series B


    Portfolio companies include:

      Alexza Pharmaceuticals
        web link

        web link

      Aptose Biosciences
        web link

        web link

      Argos Therapeutics
        web link

        web link


        web link

      Cardiac Dimensions
        web link

        web link

      DC Devices
        web link

        web link

      Engage Therapeutics
        web link

      First Aid Shot Therapy (F.A.S.T.)
        web link

      G1 Therapeutics
        web link

      KAI Pharmaceuticals
        web link

      MAKO Surgical
        web link

        web link

      Pathfiner Therapeutics
        web link

      Spinal Kinetics
        web link

      Thrasos Therapeutics
        web link

        web link

        web link

      Vascular Pharmaceuticals
        web link

      Vendor Link
        web link


    Recent News: